Triesence (triamcinolone acetonide injectable suspension) / Novartis, Harrow Health - LARVOL DELTA

A retrospective study reporting the incidence, risk factors, and intraocular pressure rise in patients receiving intravitreal steroids for retinal inflammatory diseases in a tertiary eye care hospital of South India. (PubMed, Indian J Ophthalmol) - "We found that the incidence of SI-OHT was higher in IVTA group as compared to DEX group. No dose-dependent incidence was observed in the case of IVTA group. Age, gender, number of injections, and myopia were not associated with the risk of SI-OHT. Renal disease showed a significant association with the risk of SI-OHT in the DEX group, and patients with TB, stroke, and other drug allergies experienced a fivefold greater increase in IOP values in those groups."

Journal • Retrospective data • Allergy • Cardiovascular • Diabetic Macular Edema • Glaucoma • Immunology • Inflammation • Nephrology • Ocular Inflammation • Ophthalmology • Renal Disease

Short-Term Outcomes of Intravitreal Brolucizumab Injection and Sub-Tenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema: A Pilot Study. (PubMed, J Vitreoretin Dis) - " Combination therapy with intravitreal brolucizumab and sub-Tenon triamcinolone acetonide may offer anatomic benefits in patients with DME, requiring fewer injections. Further evaluation using larger, prospectively designed studies is warranted to confirm its functional efficacy and long-term safety."

Journal • Diabetic Macular Edema • Inflammation • Ophthalmology

Management and outcomes of cataract surgery in uveitic eyes with chronic hypotony: a two-case series. (PubMed, J Ophthalmic Inflamm Infect) - "A meticulously planned, multi-modal approach-involving aggressive control of inflammation, targeted reversal of hypotony with periocular steroids, and strategic surgical timing with intentional aphakia-can lead to successful anatomical and visual outcomes in high-risk uveitic patients with cataracts and persistent hypotony."

Journal • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Transplantation • Uveitis

Evolution of the Onion Ring Sign in Radiation Retinopathy. (PubMed, Cureus) - "His clinical course included multiple intravitreal injections including triamcinolone acetonide, bevacizumab, pegaptanib, ranibizumab, aflibercept 2 and 8 mg, and dexamethasone implant...The present case demonstrates that the onion ring sign may develop in long-standing radiation retinopathy, likely reflecting the cumulative effects of chronic vascular injury and persistent macular edema. The recognition of this OCT feature may aid in understanding the natural history, chronicity, and metabolic burden of retinal vascular disorders."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Retinopathy • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders

Intravitreal triamcinolone acetonide therapy in serpiginous-like choroiditis. (PubMed, Indian J Ophthalmol) - "IVTA at a 2 mg dose appears effective in lesion resolution, while minimizing systemic therapy in SLC, with an acceptable safety profile and no paradoxical worsening. Larger prospective studies are needed to validate these findings."

Journal • Cataract • Ocular Inflammation • Ophthalmology • Uveitis

Optical Coherence Tomography (OCT) Biomarkers for Nonsurgical Management of Postvitrectomy Secondary Macular Holes With Intravitreal Triamcinolone Acetonide (1 mg/0.1 mL): A Case Report of Two Cases. (PubMed, Case Rep Ophthalmol Med) - "There have been reports on the closure of secondary macular holes with the intravitreal injection of triamcinolone acetonide, intravitreal bevacizumab, aflibercept, NSAID, and difluprednate. The identification of OCT biomarkers prior to vitrectomy can help in targeted use of nonsurgical treatment modalities in the management of secondary macular holes with the intravitreal injection of triamcinolone acetonide (1 mg/0.1 mL). Identification of OCT biomarkers can help in the nonsurgical management of secondary macular holes."

Biomarker • Journal • Macular Edema • Mood Disorders • Ophthalmology • Retinal Disorders

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema. (PubMed, Am J Ophthalmol Case Rep) - "This manuscript describes a case of recalcitrant postoperative cystoid macular edema (CME), confounded by a history of branch retinal vein occlusion (BRVO), in which faricimab resulted in resolution of CME after incomplete response to topical anti-inflammation drops, intravitreal aflibercept and bevacizumab, a corticosteroid intravitreal implant, grid laser therapy, and suprachoroidal triamcinolone acetonide (SCS-TA)...CME persisted for eight years despite treatment with topical anti-inflammatories, anti-VEGF injections, a dexamethasone intravitreal implant, grid laser therapy, and a SCS-TA injection...This case demonstrates the effectiveness of faricimab in treatment of CME resistant to other therapies and the importance of continued attempts at using new agents for chronic, recurrent CME. The unique benefits of new agents like faricimab, with both VEGF and Ang-2 inhibition, may be particularly helpful in mixed or inflammatory CME when other proven therapies have failed."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Glaucoma • Inflammation • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Retinal phlebitis complicated by punctate inner choroidopathy-like lesions: a case report. (PubMed, Am J Ophthalmol Case Rep) - "Treatment with oral prednisolone and sub-Tenon triamcinolone acetonide injections controlled the inflammation, and intravitreal aflibercept injections managed the CNV. At the two-year follow-up, the corrected visual acuity improved to 1.2. The distribution of lesions along the retinal veins suggests that this case represents a presentation of PIC-like lesions secondary to retinal phlebitis."

Journal • Inflammation • Ophthalmology • Retinal Disorders

Intraocular fate of surface charge-dependent nanomicelles via topical administration: Posterior delivery and transport pathway. (PubMed, J Control Release) - "Herein, using triamcinolone acetonide as a model drug, Soluplus® nanomicelles (NMs) with positive, negative, and neutral surface charges were prepared by the modified thin-film hydration method...In conclusion, negative and neutral NMs present promising non-invasive drug delivery systems for ocular posterior disease therapy with enhanced posterior delivery efficiency. Our study provides scientific guidance for the rational design of nanocarriers' surface charge based on the ocular diseases to be treated."

Journal • Age-related Macular Degeneration • Ophthalmology

Endophthalmitis after intravitreal injection with or without triamcinolone - A 10-year investigation in a tertiary hospital. (PubMed, Taiwan J Ophthalmol) - "This study highlights that TA is significantly associated with a higher incidence of post-IVI endophthalmitis, which is also significantly associated with culture-negative results. This implies the possibility of a noninfectious cause in TAAE."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the treatment of ocular juvenile xanthogranuloma. (PubMed, Arch Soc Esp Oftalmol (Engl Ed)) - "After numerous treatments at the 3-year follow-up, including oral steroids, repeated injections of subtenon triamcinolone acetonide and intracameral and intravitreal anti-VEGF, treatment with intravitreal fluocinolone acetonide implant (ILUVIEN®) in both eyes was decided. Evolution since then and at the 10-month follow-up has been satisfactory; the patient has not exhibited any new episodes of ocular inflammation or hyphema despite the progressive withdrawal of topical corticosteroids, and vision has remained at 20/20 in both eyes. As far as we know, this is the first case of bilateral ocular juvenile xanthogranuloma successfully treated with an intravitreal fluocinolone implant."

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report. (PubMed, Cureus) - "An 83-year-old man was referred to our clinic and diagnosed with type 1 macular neovascularization (MNV), with a previous treatment history of four doses of ranibizumab, 14 doses of aflibercept (2 mg), and two doses of faricimab...One week after subtenon triamcinolone acetonide (STTA) and topical dexamethasone, inflammation disappeared in the anterior chamber. In eyes with a history of IOI, careful attention is needed when switching to aflibercept 8 mg from another second-generation VEGF inhibitor, including faricimab."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Pain • Retinal Disorders • Wet Age-related Macular Degeneration

Effectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan. (PubMed, Clin Ophthalmol) - "If CST did not improve after the last IVBr injection, treatment was switched to intravitreal triamcinolone acetonide injection (IVTA), sub-Tenon's triamcinolone acetonide (STTA) injection, or intravitreal faricimab (IVFa)...Our findings demonstrated partial efficacy of IVBr in managing DME in vitrectomized eyes. However, variable responses often necessitate supplementary treatments to achieve therapeutic goals."

Journal • Diabetes • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology

Visual Outcomes and Safety Profile of "Dropless Vitrectomy" for Epiretinal Membranes. (PubMed, Clin Ophthalmol) - "Group 1 (N = 139) received a triamcinolone acetonide-moxifloxacin (Tri-Moxi) intravitreal injection at the conclusion of surgery, and Group 2 (N = 139) had postoperative standard topical antibiotic-steroid therapy...Intravitreal Tri-Moxi can be used as a viable treatment option for managing inflammation and preventing infection after epiretinal membrane removal by pars plana vitrectomy. Tri-Moxi group demonstrated superior anatomical outcomes and comparable functional outcomes while simplifying postoperative care and reducing the occurrence of cystoid macular edema compared to standard topical therapy."

Journal • Cardiovascular • Glaucoma • Infectious Disease • Inflammation • Macular Edema • Ocular Infections • Ophthalmology • Retinal Disorders

Intraocular Inflammation Following Faricimab Intravitreal Injection Treated With Sub-tenon Triamcinolone Acetonide Injection. (PubMed, Cureus) - "In this study, IOI was managed with a STTA injection during the early stage of uveitis. Severe inflammation can lead to complications such as posterior iris synechia."

Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Predictive value of short-term steroid intraocular pressure elevation testing for long-term steroid intraocular pressure elevation in diabetic macular edema treatment. (PubMed, Int Ophthalmol) - "It is crucial to evaluate the necessity of a prior short-acting steroid challenge, which carries the risk of multiple disease relapses, given the potential for a prolonged and stable steroid to provide superior control. The predictive value of the test with TA was not evident in our sample, suggesting some usefulness in delaying treatment with the FAc implant."

Journal • Observational data • Retrospective data • Diabetic Macular Edema • Ophthalmology

Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema. (PubMed, Jpn J Ophthalmol) - "IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored."

Journal • Real-world evidence • Diabetic Macular Edema • Inflammation • Ocular Inflammation • Ophthalmology

Revisiting the Role of Intravitreal Triamcinolone in Diabetic Macular Edema: 12-Month Outcomes after Bevacizumab Failure. (PubMed, Ophthalmol Ther) - "Repeated IVTA treatments for DME refractory to bevacizumab over a 12-month period demonstrated efficacy and appeared to have a comparable safety profile. Patients with thinner CMT before IVTA treatment had a greater probability of remaining DME-free after IVTA treatment."

Journal • Diabetic Macular Edema • Ophthalmology

Treatment of Non-Infectious Uveitis Macular Edema Using Two Doses of Triamcinolone Acetonide: Comparative Study. (PubMed, Ocul Immunol Inflamm) - "Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up."

Journal • Cardiovascular • Cataract • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

Beyond the injection: delivery systems reshaping retinal disease management. (PubMed, Expert Opin Pharmacother) - "Specific innovations discussed include the ranibizumab port delivery system, EYP-1901 (Duravyu, vorolanib implant), KSI-301 (tarcocimab tedromer), KSI-501, OTX-TKI (Axpaxli, axitinib implant), 4D-150, revakinagene taroretcel-lwey (Encelto, NT-501, encapsulated cell therapy), Xipere (triamcinolone acetonide injectable suspension), AU-011 (belzupacap sarotalocan targeted delivery), ABBV-RGX-314, elamipretide, and OCS-01 (high concentration dexamethasone)...Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders

Changes of diabetic macular edema post vitrectomy in patients with proliferative diabetic retinopathy. (PubMed, Int J Ophthalmol) - "PV-DME is a very common postoperative complication in patients with PDR. Triamcinolone acetonide could prevent its formation. Attention should be paid to patients with a thicker preoperative CRT and internal limiting membrane peeling."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations. (PubMed, J Control Release) - "Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route."

Journal • Preclinical • Ophthalmology

Intravitreal low-dose triamcinolone acetonide for nonarteritic anterior ischemic optic neuropathy. (PubMed, Int J Ophthalmol) - "Low-dose IVTA may be an alternative safe treatment option for some NAION patients in the acute stage. However, optic nerve atrophy still existed."

Journal • Cardiovascular • Diabetic Retinopathy • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders

Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis. (PubMed, JAMA Ophthalmol) - "Five randomized clinical trials were preselected for analysis, including the RIDE and RISE trials (Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus); Protocol I (Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema), Protocol S (Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy), and Protocol T (A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema)...No difference in BCVA was observed in Black vs White participants at 2 years. Smaller enrollment numbers precluded analysis of participants of other races, suggesting lack of robust diversity beyond Black and White participants in these trials."

Clinical • Journal • Retrospective data • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Occlusive Retinal Vasculitis After Aflibercept 8mg Injection for Wet Macular Degeneration. (PubMed, Retin Cases Brief Rep) - "ORV is a rare complication of some intravitreal anti-VEGF medications and infectious causes of endophthalmitis. It can be managed with aggressive steroid treatment for an excellent visual outcome in some cases, although the disease may be chronic or recurrent."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration